Freenome, developer of exams that establish early indicators of most cancers from a small pattern of affected person blood, goes public in a merger deal that can infuse the corporate with $330 million to help a pipeline that would yield its first commercialized check in 2026.
The early most cancers detection firm is merging with Perceptive Capital Options Corp, a particular function acquisition firm (SPAC) sponsored by an affiliate of Perceptive Advisors, the corporations introduced Friday. The mixed firm will take the Freenome title. When the deal closes, Freenome’s inventory is anticipated to commerce on the Nasdaq beneath the inventory image “FRNM.”
Brisbane, California-based Freenome is a part of a gaggle of corporations creating exams that detect organic and genetic indicators of most cancers by analyzing a small pattern of affected person blood, a so-called liquid biopsy. Freenome’s platform know-how makes use of synthetic intelligence and machine studying methods to investigate samples and establish most cancers indicators. Such exams are supposed to detect most cancers on the earliest levels of illness when therapy has a higher likelihood of success. Early most cancers detection represents a $50 billion market alternative, Freenome stated in an investor presentation.
A colorectal most cancers check is Freenome’s most superior product candidate. This check, known as SimpleScreen, is at present beneath FDA overview with a regulatory determination anticipated in mid-2026. Freenome’s fundamental competitor in colorectal most cancers detection will likely be Guardant Well being, whose Defend check was the primary FDA-approved liquid biopsy for this sort of most cancers. Actual Sciences was anticipated to compete with its personal check, however medical trial outcomes from a pivotal research have been disappointing. Subsequently, Actual struck a cope with Freenome in August, paying $75 million up entrance for U.S. rights to SimpleScreen for the one indication of colorectal most cancers screening.
The Actual Sciences deal permits Freenome to maintain rights to colorectal most cancers screening as a part of a multi-cancer detection check it’s creating to display screen for greater than 10 cancers from a pattern of affected person blood. Roche, which already has an current relationship with Freenome as an investorfinal month reached a deal securing rights to commercialize the corporate’s “kitted” multi-cancer early detection exams exterior of the U.S. Kitted exams package deal the assay and software program collectively to allow processing and evaluation of a pattern without having a centralized lab. This deal got here with a $75 million upfront fairness funding in Freenome; one other $134 million is tied to the achievement of milestones. Freenome retains rights to U.S. multi-cancer early detection testing in addition to U.S. rights to kitted exams.
Freenome is pursuing a “versioning technique” wherein assay and algorithm enhancements will likely be included into later variations of its exams. The regulatory submission at present beneath FDA overview is for model 1 of SimpleScreen. The corporate expects a regulatory submission for model 2 will likely be prepared by the center of subsequent yr. The investor presentation provides a peek into these knowledge, exhibiting 75% sensitivity for detecting stage I colorectal most cancers; sensitivities for superior adenoma and high-grade dysplasia have been 22% and 44% respectively. Whereas these marks prime the outcomes reported for model 2 of Guardant’s Defend, William Blair analyst Andrew Brackmann stated in a analysis be aware that the model 2 knowledge for SimpleScreen is the ultimate medical validation knowledge and never the pivotal knowledge anticipated to be submitted to the FDA.
“We, not surprisingly, have questions relating to how this research was run, the place the cancers are from, and so forth., however even nonetheless, outcomes do present some good enchancment versus v1,” Brackmann stated.
Guardant’s Defend has first mover benefit available in the market, projected to do greater than 80,000 exams this yr, Leerink Companions analyst Puneet Souda stated in a analysis be aware. With the second model of SimpleScreen not anticipated to be filed till the second half of subsequent yr, Guardant has time to enhance its subsequent check, Defend model 3. However Leerink sees the marketplace for liquid biopsies as massive, with about 11 million average-risk people prepared to be screened with a blood check however not a colonoscopy. That leaves room for a number of rivals, Souda stated.
Since its 2014 founding, Freenome had raised greater than $1.3 billion, the corporate stated within the investor presentation. The SPAC merger is anticipated to infuse the corporate with about $330 million. That sum breaks right down to $90 million from a belief account held by Perceptive Capital Options and a $240 million personal funding in public fairness (PIPE) led by Perceptive Advisors and RA Capital. The traders within the PIPE will buy 24 million Freenome shares on the worth of $10 every.
Including Freenome’s personal funds, which incorporates funds from the Actual Sciences and Roche offers, the corporate expects to have greater than $1.3 billion complete when the merger closes, in accordance with the presentation. Proceeds from the transaction and money readily available will likely be utilized towards product improvement, medical testing, and commercialization actions.
The Freenome and Perceptive Capital Options boards of administrators have accepted the merger, which is anticipated to shut within the first half of 2026. The deal nonetheless wants the approval of shareholders of each corporations.
Photograph: MilosJokic, Getty Pictures
